Hot Selling GS-6207 2189684-44-2 Factory Supply Raw Materials High Qulity Wholesale price
TDS 1 Inquiries
2189684-44-2
USP / EP / BP / JP Grade
99%
shanghai
bocare
25kg/Cardboard Drum
2026-06-22
pregabalin,Tirzepatide,Retatrutide,Food Additives,semaglutide,Cosmetics material
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceLenacapavir is under investigation in clinical trial NCT04150068 (Study to Evaluate the Safety and Efficacy of Lenacapavir in Combination With an Optimized Background Regimen in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance).
HIV-1 capsid inhibitor GS-6207 (lenacapavir) is a drug being developed by Gilead Sciences, Inc. It is a first-in-class, oral HIV-1 capsid inhibitor.CertificatesBasic Info-
Product Name:
Lenacapavir
Other Name:GS-6207;Lenacapavir;1H-Cyclopropa[3,4]cyclopenta[1,2]pyrazole-1-acetamide, N-[(1S)-1-[3-[4-chloro-3-[(methylsulfonyl)amino]-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl]-6-[3-methyl-3-(methylsulfonyl)-1-butyn-1-yl]-2-pyridinyl]-2-(3,5-difluorophenyl)ethyl]-5,5-difluoro-3b,4,4a,5-tetrahydro-3-(trifluoromethyl)-, (3bS,4aR)-;13C,2H3]-Lenacapavir , isomeric mixture;MT-4,Inhibitor,antiretroviral,Lenacapavir,inhibit,GS 6207,capsid,Human immunodeficiency virus,HIV,GS6207,HIV-1,PBMCs;1H-Cyclopropa[3,4]cyclopenta[1,2-c]pyrazole, N-[(1S)-1-[3-[4-chloro-3-[(methylsulfonyl)amino]-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl]-6-[3-methyl-3-(methylsulfonyl)-1-butyn-1-yl]-2-pyridinyl]-2-(3,5-difluorophenyl)ethyl]-5,5-difluoro-3b,4,4a,5-tetrahydro-3-(trifluoromethyl)-, (3bS,4aR)-;Sunitinib Impurity 72;13C,2H3]-Lenacapavir (Major),isomers mixture
CAS No.:2189684-44-2
Molecular Formula:C39H32ClF10N7O5S2
InChIKeys:BRYXUCLEHAUSDY-WEWMWRJBSA-N
Molecular Weight:968.28
Exact Mass:967.1435188
UNII:A9A0O6FB4H
Color/Form:White to light yellow
Categories:
Characteristics-
Density:
1.62±0.1 g/cm3(Predicted)
PKA:4.63±0.30(Predicted)
Critical Temperature & Pressure:Store at -20°C
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
pregabalin,Tirzepatide,Retatrutide,Food Additives,semaglutide,Cosmetics material
-
Location:
Jiuzhen Town, Tianmen City, Hubei Province
-
Payment Terms:
TT against copy of documents,L/C,100% TT in advance
-
Average lead Time:
7
-
Total Annual Revenue:
$50 million-$100 million
-
Total Employees:
101-200
-
Year of Establishment:
2025
-
-
Inquiry History1 Inquiries
Country Product Purchase Quantity Date Posted
South Korea
2189684-44-2
10 G Dec 2, 2024 Post an enquiry for this product
